Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2011

View Archived Issues

Targacept begins phase II trials of TC-6987 in asthma and type 2 diabetes

IntelGenx's INT-0022 shows bioequivalence to a leading antipsychotic

Gilead resubmits NDA for single-tablet Truvada/TMC-278 regimen in HIV-1

Protein S100-A12 levels correlate with pathological activity in Behcet's disease / News in Context

Botulinum neurotoxin type A is efficacious in urological disorders

PF-04605412 displays marked antitumor effects in vivo

Dentin matrix acidic phosphoprotein 1 plays a role in angiogenesis

Mallinckrodt describes new prodrugs of hydromorphone

New deuterated 2,4-pyrimidinediamines claimed for autoimmune diseases

New urotensin UT receptor antagonists divulged

Taisho Pharma patents new inhibitors of GlyT1

Sareum provides update on Aurora+FLT3 kinase program

Promedior begins phase Ib PRM-151 trial in idiopathic pulmonary fibrosis

Theravance identifies novel inhibitors of NET and 5HTT

Neuralstem provides update on stem cell study for ALS

INX-08189 receives FDA fast track status in chronic hepatitis C

Intellikine and PKD Foundation collaborate on treatment of polycystic kidney disease

Genta begins tesetaxel trial in advanced prostate cancer

Candesartan heart failure therapy is associated with lower all-cause mortality than losartan

Alexion acquires investigational therapy for molybdenum cofactor deficiency

Zogenix completes enrollment in phase III efficacy trial of ZX-002

Renovo's phase III REVISE trial of Juvista does not meet primary or secondary endpoints

Medivir and Janssen enter R&D collaboration for dengue virus infection

Eisai and Teikoku Seiyaku enter license agreement for transdermal Aricept in Japan

BioSante to continue enrollment in phase III LibiGel program following safety review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 12, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026